Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
The PD1/PD-L1 pathway may be a target for the treatment of T-cell lymphomas. Here, we treated 18 patients with relapsed or refractory T-cell lymphoma with the PD1-inhibitor pembrolizumab. Although we did not meet our primary objective of improving progression-free survival from 3 to 6 months, 5 of 1...
Gespeichert in:
| Veröffentlicht in: | Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2019-04, Vol.19 (6), p.356-364.e3 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 364.e3 |
|---|---|
| container_issue | 6 |
| container_start_page | 356 |
| container_title | Clinical lymphoma, myeloma and leukemia |
| container_volume | 19 |
| creator | Barta, Stefan K. Zain, Jasmine MacFarlane, Alexander W. Smith, Sonali M. Ruan, Jia Fung, Henry C. Tan, Carlyn R. Yang, Yibin Alpaugh, R. Katherine Dulaimi, Essel Ross, Eric A. Campbell, Kerry S. Khan, Nadia Siddharta, Rawat Fowler, Nathan H. Fisher, Richard I. Oki, Yasuhiro |
| description | The PD1/PD-L1 pathway may be a target for the treatment of T-cell lymphomas. Here, we treated 18 patients with relapsed or refractory T-cell lymphoma with the PD1-inhibitor pembrolizumab. Although we did not meet our primary objective of improving progression-free survival from 3 to 6 months, 5 of 13 evaluable patients showed a response providing a benchmark for future studies. |
| doi_str_mv | 10.1016/j.clml.2019.03.022 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7433797</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_7433797</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_74337973</originalsourceid><addsrcrecordid>eNqljE1Lw0AYhBdRbKv-AU_7BxL3o03IxYsfWFAIbe_Lm-SN2bKbDZuNEH-9WyiCZ08zzDwzhNxzlnLGs4djWhtrUsF4kTKZMiEuyFLwjUhElhWXv37DFmQ1jkfGchbZa7KQnIkiW2dLEsoORqTbLd2HqZmpa2nokJbPPNF9pysdnKcl2so7o78nCxVtY3JiDh4hWOzDabRDA8OIDY3lDlsPdRzO9APC5COa1GgMfZ_t0DkLt-SqBTPi3VlvyOPry-HpLRmmymJTx08PRg1eW_CzcqDV36bXnfp0XypfS5kXufz3wQ_6N2uP</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma</title><source>Elsevier ScienceDirect Journals</source><creator>Barta, Stefan K. ; Zain, Jasmine ; MacFarlane, Alexander W. ; Smith, Sonali M. ; Ruan, Jia ; Fung, Henry C. ; Tan, Carlyn R. ; Yang, Yibin ; Alpaugh, R. Katherine ; Dulaimi, Essel ; Ross, Eric A. ; Campbell, Kerry S. ; Khan, Nadia ; Siddharta, Rawat ; Fowler, Nathan H. ; Fisher, Richard I. ; Oki, Yasuhiro</creator><creatorcontrib>Barta, Stefan K. ; Zain, Jasmine ; MacFarlane, Alexander W. ; Smith, Sonali M. ; Ruan, Jia ; Fung, Henry C. ; Tan, Carlyn R. ; Yang, Yibin ; Alpaugh, R. Katherine ; Dulaimi, Essel ; Ross, Eric A. ; Campbell, Kerry S. ; Khan, Nadia ; Siddharta, Rawat ; Fowler, Nathan H. ; Fisher, Richard I. ; Oki, Yasuhiro</creatorcontrib><description>The PD1/PD-L1 pathway may be a target for the treatment of T-cell lymphomas. Here, we treated 18 patients with relapsed or refractory T-cell lymphoma with the PD1-inhibitor pembrolizumab. Although we did not meet our primary objective of improving progression-free survival from 3 to 6 months, 5 of 13 evaluable patients showed a response providing a benchmark for future studies.</description><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2019.03.022</identifier><identifier>PMID: 31029646</identifier><language>eng</language><ispartof>Clinical lymphoma, myeloma and leukemia, 2019-04, Vol.19 (6), p.356-364.e3</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids></links><search><creatorcontrib>Barta, Stefan K.</creatorcontrib><creatorcontrib>Zain, Jasmine</creatorcontrib><creatorcontrib>MacFarlane, Alexander W.</creatorcontrib><creatorcontrib>Smith, Sonali M.</creatorcontrib><creatorcontrib>Ruan, Jia</creatorcontrib><creatorcontrib>Fung, Henry C.</creatorcontrib><creatorcontrib>Tan, Carlyn R.</creatorcontrib><creatorcontrib>Yang, Yibin</creatorcontrib><creatorcontrib>Alpaugh, R. Katherine</creatorcontrib><creatorcontrib>Dulaimi, Essel</creatorcontrib><creatorcontrib>Ross, Eric A.</creatorcontrib><creatorcontrib>Campbell, Kerry S.</creatorcontrib><creatorcontrib>Khan, Nadia</creatorcontrib><creatorcontrib>Siddharta, Rawat</creatorcontrib><creatorcontrib>Fowler, Nathan H.</creatorcontrib><creatorcontrib>Fisher, Richard I.</creatorcontrib><creatorcontrib>Oki, Yasuhiro</creatorcontrib><title>Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma</title><title>Clinical lymphoma, myeloma and leukemia</title><description>The PD1/PD-L1 pathway may be a target for the treatment of T-cell lymphomas. Here, we treated 18 patients with relapsed or refractory T-cell lymphoma with the PD1-inhibitor pembrolizumab. Although we did not meet our primary objective of improving progression-free survival from 3 to 6 months, 5 of 13 evaluable patients showed a response providing a benchmark for future studies.</description><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqljE1Lw0AYhBdRbKv-AU_7BxL3o03IxYsfWFAIbe_Lm-SN2bKbDZuNEH-9WyiCZ08zzDwzhNxzlnLGs4djWhtrUsF4kTKZMiEuyFLwjUhElhWXv37DFmQ1jkfGchbZa7KQnIkiW2dLEsoORqTbLd2HqZmpa2nokJbPPNF9pysdnKcl2so7o78nCxVtY3JiDh4hWOzDabRDA8OIDY3lDlsPdRzO9APC5COa1GgMfZ_t0DkLt-SqBTPi3VlvyOPry-HpLRmmymJTx08PRg1eW_CzcqDV36bXnfp0XypfS5kXufz3wQ_6N2uP</recordid><startdate>20190403</startdate><enddate>20190403</enddate><creator>Barta, Stefan K.</creator><creator>Zain, Jasmine</creator><creator>MacFarlane, Alexander W.</creator><creator>Smith, Sonali M.</creator><creator>Ruan, Jia</creator><creator>Fung, Henry C.</creator><creator>Tan, Carlyn R.</creator><creator>Yang, Yibin</creator><creator>Alpaugh, R. Katherine</creator><creator>Dulaimi, Essel</creator><creator>Ross, Eric A.</creator><creator>Campbell, Kerry S.</creator><creator>Khan, Nadia</creator><creator>Siddharta, Rawat</creator><creator>Fowler, Nathan H.</creator><creator>Fisher, Richard I.</creator><creator>Oki, Yasuhiro</creator><scope>5PM</scope></search><sort><creationdate>20190403</creationdate><title>Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma</title><author>Barta, Stefan K. ; Zain, Jasmine ; MacFarlane, Alexander W. ; Smith, Sonali M. ; Ruan, Jia ; Fung, Henry C. ; Tan, Carlyn R. ; Yang, Yibin ; Alpaugh, R. Katherine ; Dulaimi, Essel ; Ross, Eric A. ; Campbell, Kerry S. ; Khan, Nadia ; Siddharta, Rawat ; Fowler, Nathan H. ; Fisher, Richard I. ; Oki, Yasuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_74337973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barta, Stefan K.</creatorcontrib><creatorcontrib>Zain, Jasmine</creatorcontrib><creatorcontrib>MacFarlane, Alexander W.</creatorcontrib><creatorcontrib>Smith, Sonali M.</creatorcontrib><creatorcontrib>Ruan, Jia</creatorcontrib><creatorcontrib>Fung, Henry C.</creatorcontrib><creatorcontrib>Tan, Carlyn R.</creatorcontrib><creatorcontrib>Yang, Yibin</creatorcontrib><creatorcontrib>Alpaugh, R. Katherine</creatorcontrib><creatorcontrib>Dulaimi, Essel</creatorcontrib><creatorcontrib>Ross, Eric A.</creatorcontrib><creatorcontrib>Campbell, Kerry S.</creatorcontrib><creatorcontrib>Khan, Nadia</creatorcontrib><creatorcontrib>Siddharta, Rawat</creatorcontrib><creatorcontrib>Fowler, Nathan H.</creatorcontrib><creatorcontrib>Fisher, Richard I.</creatorcontrib><creatorcontrib>Oki, Yasuhiro</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barta, Stefan K.</au><au>Zain, Jasmine</au><au>MacFarlane, Alexander W.</au><au>Smith, Sonali M.</au><au>Ruan, Jia</au><au>Fung, Henry C.</au><au>Tan, Carlyn R.</au><au>Yang, Yibin</au><au>Alpaugh, R. Katherine</au><au>Dulaimi, Essel</au><au>Ross, Eric A.</au><au>Campbell, Kerry S.</au><au>Khan, Nadia</au><au>Siddharta, Rawat</au><au>Fowler, Nathan H.</au><au>Fisher, Richard I.</au><au>Oki, Yasuhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><date>2019-04-03</date><risdate>2019</risdate><volume>19</volume><issue>6</issue><spage>356</spage><epage>364.e3</epage><pages>356-364.e3</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><abstract>The PD1/PD-L1 pathway may be a target for the treatment of T-cell lymphomas. Here, we treated 18 patients with relapsed or refractory T-cell lymphoma with the PD1-inhibitor pembrolizumab. Although we did not meet our primary objective of improving progression-free survival from 3 to 6 months, 5 of 13 evaluable patients showed a response providing a benchmark for future studies.</abstract><pmid>31029646</pmid><doi>10.1016/j.clml.2019.03.022</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2152-2650 |
| ispartof | Clinical lymphoma, myeloma and leukemia, 2019-04, Vol.19 (6), p.356-364.e3 |
| issn | 2152-2650 2152-2669 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7433797 |
| source | Elsevier ScienceDirect Journals |
| title | Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A09%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20Study%20of%20the%20PD1-inhibitor%20Pembrolizumab%20for%20the%20Treatment%20of%20Relapsed%20or%20Refractory%20Mature%20T-cell%20Lymphoma&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Barta,%20Stefan%20K.&rft.date=2019-04-03&rft.volume=19&rft.issue=6&rft.spage=356&rft.epage=364.e3&rft.pages=356-364.e3&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2019.03.022&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_7433797%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31029646&rfr_iscdi=true |